Phase 2a Study of VTX3232 in Parkinson's Disease

Inclusion Criteria:

• Participants must be ≥ 40 years up to 80 years of age, inclusive, at the time ofsigning the informed consent, with BMI > 18.5 and < 32.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.

• Diagnosis of idiopathic Parkinson's Disease between 0 and 60 months prior toscreening.

• Score of 2 or less on Movement Disorder Society-Unified Parkinson's Disease RatingScale (MDS-UPDRS) Part IV at screening.

• Have not received prior treatment with deep brain stimulation (DBS).

• If receiving treatment with symptomatic PD therapies, treatment must be stable.Note: The Medical Monitor should be contacted with any questions regardingconcomitant therapies.

• A female participant is eligible if they are of nonchildbearing potential

• A male participant sexually active with a woman of child bearing potential iseligible if they agree to use contraception/barrier and refrain from donating spermduring the study and for at least 90 days after the last dose

Exclusion Criteria:

• Diagnosis of a Parkinsonian syndrome other than idiopathic Parkinson's Disease.

• A diagnosis of a significant central nervous system (CNS) disease other thanParkinson's disease; history of repeated head injury or traumatic brain injury;history of epilepsy or seizure disorder other than febrile seizures as a child.

• History of brain surgery.